Cocrystallization of multi-kinase inhibitor pazopanib with fenamic acids: improving dissolution and inhibiting cell migration-Reference-Cited by-同舟云学术

Cocrystallization of multi-kinase inhibitor pazopanib with fenamic acids: improving dissolution and inhibiting cell migration

Published:2023 Issue:39 Volume:25 Page:5565-5574
ISSN:1466-8033
Container-title:CrystEngComm
language:en
Short-container-title:CrystEngComm

Author:

Rai Sunil K.¹²^ORCID,Gunnam Anilkumar³^ORCID,Roy Debopriya⁴⁵,Rajput Raveena⁴,Kulkarni Kiran⁴⁵^ORCID,Nangia Ashwini K.³²^ORCID

Affiliation:

1. Department of Chemistry, Faculty of Science, University of Lucknow, Lucknow, Uttar Pradesh 226007, India

2. Division of Organic Chemistry, CSIR – National Chemical Laboratory, Dr. Homi Bhabha Road, Pune 411008, India

3. School of Chemistry, University of Hyderabad, Prof. C. R. Rao Road, Gachibowli, Central University P.O., Hyderabad 500 046, India

4. Biochemical Sciences Division, CSIR – National Chemical Laboratory, Dr. Homi Bhabha Road, Pune-411008, India

5. Academy of Scientific and Innovative Research (AcSIR), New Delhi-110025, India

Abstract

Multi-drug crystalline salts of pazopanib with fenamic acids exhibit enhanced dissolution and 20% higher inhibition in the migration of HUVEC cells compared to the reference drug.

Funder

Science and Engineering Research Board

University Grants Commission

Department of Science and Technology, Ministry of Science and Technology, India

Publisher

Royal Society of Chemistry (RSC)

Subject

Condensed Matter Physics,General Materials Science,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/CE/D3CE00773A

Reference49 articles.

1. The role of pazopanib on tumour angiogenesis and in the management of cancers: A review

2. U.S. FDA , Center for Drug Evaluation and Research, available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf (accessed on 11-01- 2023 )

3. Prescribing Information for VOTRIENT https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s-010S-012lbl.pdf (accessed on 11-01- 2023 )

4. Summary of product characteristics: https://www.ema.europa.eu/en/documents/product-information/votrient-epar-product-information_en.pdf (accessed on 11-01- 2023 )